These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18184032)

  • 1. Fondaparinux: use in thromboprophylaxis of acute medical patients.
    Dhillon S; Plosker GL
    Drugs Aging; 2008; 25(1):81-8. PubMed ID: 18184032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.
    Reynolds NA; Perry CM; Scott LJ
    Drugs; 2004; 64(14):1575-96. PubMed ID: 15233593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism.
    Robinson DM; Wellington K
    Am J Cardiovasc Drugs; 2005; 5(5):335-46. PubMed ID: 16156690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PK evaluation of fondaparinux sodium for the treatment of thrombosis.
    Delavenne X; Frappé P; Zufferey P; Mismetti P; Laporte S; Bertoletti L
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):269-77. PubMed ID: 24359588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fondaparinux: pharmacology and clinical experience in cardiovascular medicine.
    Toschi V; Lettino M
    Mini Rev Med Chem; 2007 Apr; 7(4):383-7. PubMed ID: 17430224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monitoring anticoagulation by fondaparinux: determination of anti factor Xa-level].
    Dämgen-von Brevern G; Kläffling C; Lindhoff-Last E
    Hamostaseologie; 2005 Aug; 25(3):281-5. PubMed ID: 16113752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fondaparinux: an update on new study results.
    Bauersachs RM
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():27-32. PubMed ID: 15701145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on fondaparinux sodium in acute coronary syndromes.
    Blick SK; Orman JS; Wagstaff AJ; Scott LJ
    BioDrugs; 2008; 22(6):413-5. PubMed ID: 18998758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.
    Cohen AT; Davidson BL; Gallus AS; Lassen MR; Prins MH; Tomkowski W; Turpie AG; Egberts JF; Lensing AW;
    BMJ; 2006 Feb; 332(7537):325-9. PubMed ID: 16439370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin pentasaccharide.
    Gallus AS; Coghlan DW
    Curr Opin Hematol; 2002 Sep; 9(5):422-9. PubMed ID: 12172461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux: an overview.
    Nadar SK; Goyal D; Shantsila E; Banerjee P; Lip GY
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):577-85. PubMed ID: 19505272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
    Blick SK; Orman JS; Wagstaff AJ; Scott LJ
    Am J Cardiovasc Drugs; 2008; 8(2):113-25. PubMed ID: 18422394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
    Turpie AG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fondaparinux sodium.
    Reverter JC
    Drugs Today (Barc); 2002 Mar; 38(3):185-94. PubMed ID: 12532174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fondaparinux (Arixtra): a new anticoagulant.
    Giangrande PL
    Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of acute coronary syndromes with fondaparinux.
    Wienbergen H; Zeymer U
    Vasc Health Risk Manag; 2007; 3(3):321-9. PubMed ID: 17703640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.